![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Abzena, a global partner research organization for integrated bench to market solutions for biologics and bioconjugates, has announced upgrades of its chemistry GMP suites.
The Bristol PA site manufacturing facility upgrades allow Abzena’s ADC client projects to seamlessly progress from discovery to commercial without technology transfer.
The Bristol site enhancements includes two new GMP suites, one for small molecules, including high potency up to 100L scale, and one for conjugation, as well as other GMP facility upgrades.
Jonathan Goldman, CEO of Abzena said; “Customer demand for our high quality, integrated services has increased 93% since 2019. This has driven our decision to invest in our capacity for commercial GMP capacity for ADCs. We are delighted to augment our market leading discovery, design and development capability and add to our outstanding scientific team.”
Abzena also recently announced senior leadership appointments at the Bristol site. These include Giovanni Escobar, as SVP and site head, who joined the company from a senior role at GSK and Anu Bansal, as Senior Director of manufacturing, formerly a leader in manufacturing at Genentech. Both leaders bring a wealth of experience in the journey from discovery to market of ADCs.
Dr. Goldman continued: “Abzena is committed to being the best-in-class provider of fully integrated drug discovery and development services of biologics and ADC, supported by unrivalled experience. We look forward to supporting our partners and the patients they serve.”
About Abzena
Abzena is a leading contract provider of integrated discovery, development and manufacturing services for biologics and bioconjugates. Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK.
